Can a simple blood test tell us when to switch, stop, or add breast cancer treatment?

In Episode 5 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar are joined by Dr. Heather Parsons and patient advocate Julia Maués to explore the evolving role of circulating tumor DNA (ctDNA) in breast cancer treatment decisions.

From SERENA-6 and switching therapy before radiographic progression to HER2CLIMB-05, the STOP-HER2 trial, and AFT-70 NAVIGATE, the conversation examines how ctDNA could help guide treatment escalation, de-escalation, and personalized care.

Beyond the data, they tackle the unanswered questions: When should clinicians act on molecular findings? Can some patients safely stop treatment? And how do we balance promising innovations with treatment burden, toxicity, and patient preferences?

▶️ Watch on YouTube - https://youtu.be/Mh2uNBGrRLI

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio: https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #ctDNA #BreastCancer #SERENA6 #STOPHER2 #NAVIGATETrial #MetastaticBreastCancer #PrecisionOncology #MedicalOncology #CommunityHealthMedia

One trial. One therapy. Countless clinical questions.

In Episode 4 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar take a deep dive into the VIKTORIA-1 trial and discuss how gedatolisib may reshape treatment for patients with HR-positive, HER2-negative metastatic breast cancer.

Beyond reviewing the data, they explore where this regimen fits in clinical practice, who may benefit most, concerns surrounding toxicity and treatment burden, and how VIKTORIA-1 compares with other rapidly emerging therapies in this evolving treatment landscape.

Topics discussed:

VIKTORIA-1 trial design and key efficacy results

Gedatolisib triplet vs. doublet therapy

Managing HR-positive, HER2-negative metastatic breast cancer

Intravenous therapy vs. oral treatment options

Stomatitis and other treatment-related toxicities

Patient selection and co-mutations

How PAM pathway inhibition may overcome resistance

Sequencing endocrine therapies after progression

Emerging trials including FOURLIGHT-1 and selective CDK4 inhibitors

The future of targeted therapy in metastatic breast cancer

Recorded prior to the July 2026 FDA approval of gedatolisib (Revtorpyk) with fulvestrant, ± palbociclib, for HR-positive, HER2-negative advanced breast cancer without a detectable PIK3CA mutation after progression on prior endocrine therapy.

▶️ Watch on YouTube - https://youtu.be/43BVZ9nL424

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - https://linkin.bio/cancerunfilteredpodcast/

#CancerUnfiltered #VIKTORIA1 #Gedatolisib #HRPositive #MetastaticBreastCancer #MedicalOncology #BreastCancer #PI3K #PIK3CA #TargetedTherapy #CommunityHealthMedia

Breast cancer treatment is changing at an unprecedented pace.

In Episode 3 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar discuss the latest FDA approvals, landmark clinical trials, and emerging treatment strategies that are reshaping care across HR-positive, HER2-positive, and triple-negative breast cancer. From practice-changing DESTINY data to the expanding role of antibody-drug conjugates, this episode breaks down what the latest evidence means for treatment decisions today.

Topics discussed:

• Six new FDA approvals across all major breast cancer subtypes

• Vepdegestrant and the VERITAC-2 trial for ESR1-mutant HR-positive breast cancer

• DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09: key findings and clinical impact

• The growing role of antibody-drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer

• Treatment sequencing and how new approvals are changing clinical decision-making

• Which HER2-positive patients may benefit most from the DESTINY-Breast09 approach

• Brain metastases, PIK3CA mutations, and selecting therapy for high-risk patients

• Giredestrant and the lidERA trial: improving endocrine therapy options

• VIKTORIA-1 and emerging therapies targeting the PI3K/AKT/mTOR (PAM) pathway

• The future of breast cancer treatment and practice-changing data to watch

Whether you're an oncologist, advanced practice provider, researcher, or healthcare professional, this episode offers practical insights into the rapidly evolving breast cancer treatment landscape and what these developments mean for patient care.

▶️ Watch on YouTube - https://youtu.be/m0l8feuG6Y8

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #FDAApprovals #DESTINYBreast11 #DESTINYBreast05 #Vepdegestrant #TripleNegativeBreastCancer #HER2Positive #CancerPodcast #CommunityHealthMedia